Aadi bioscience announces poster presentations at the 2024 american society of clinical oncology (asco) gastrointestinal (gi) cancers symposium

- new real-world analysis highlights unmet medical need in gi cancer patients with tsc1/2 alterations- los angeles , jan. 19, 2024 /prnewswire/ -- aadi bioscience, inc. (nasdaq: aadi), a biopharmaceutical company focused on developing and commercializing precision therapies for patients with mtor pathway alterations, today announced poster presentations at the 2024 american society of clinical oncology (asco) gastrointestinal (gi) cancers symposium, taking place january 18-20, 2024, in san francisco, ca.  abstract and poster presentation details are below: title: "real-world analysis of patients with advanced gastrointestinal (gi) cancers harboring inactivating tsc1 and tsc2 alterations using the foundation medicine genomic database" session title: poster session b: cancers of the pancreas, small bowel, and hepatobiliary tractdate/time: january 19, 2024 – 12:30 – 2:00 pm abstract: 558presenting author: dustin deming, md abstract highlights: in a large real-world database of patients with advanced cancer, 1,898 (1.4%) of the 138,671 patients with gi cancers harbored at least one known or likely inactivating alteration in tsc1 or tsc2 tsc1 and/or tsc2 inactivating alterations were present in 6.8% of liver cancers, 1.6% of colorectal cancers, and 0.5% of pancreatic cancers across gi malignancies, genes frequently mutated in tumors with wild-type tsc1 and tsc2 were similar to genetic mutations co-occurring in tumors with alterations in tsc1 and/or tsc2 most tsc1 and/or tsc2 inactivating alterations in liver and pancreatic cancers occurred in the context of low tmb and mss tumors; whereas increased tmb and msi signatures were enriched in colorectal cancer with tsc1 and/or tsc2 alterations limitations of this exploratory, real-world study include the timing of sampling (at initial diagnosis vs disease progression) and the absence of clinically matched outcomes data.
AADI Ratings Summary
AADI Quant Ranking